By Timothy S. Donahue
Top Takeaways:
- Nomination Pulled: The White House withdrew Heidi Overton’s nomination hours before a scheduled Senate committee vote.
- Vaping Divide: Former administration officials accused Overton of helping relax regulatory standards for fruit-flavored vapor products.
- Leadership Limbo: Acting Commissioner Kyle Diamantas remains in charge as Republicans reportedly consider another candidate.
Flavored vapes have become another headache in Trump’s search for an FDA chief.
The White House withdrew Heidi Overton’s nomination to lead the Food and Drug Administration on November 17, following mounting political opposition, including disagreements within the Republican Party over the administration’s approach to flavored vapor products.
The decision came hours before the Senate Health, Education, Labor and Pensions (HELP) Committee was set to vote on her nomination Wednesday.
Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated in August to replace Marty Makary, who resigned in May following disagreements with the administration over several issues, including flavored e-cigarettes.
Nicotine Insider previously reported that Makary has publicly alleged that White House officials pressured the FDA to ease access to fruit-flavored vapor products, raising questions about political influence on the agency’s regulatory decisions.
Overton subsequently drew criticism from prominent figures associated with Health and Human Services Secretary Robert F. Kennedy Jr.’s Make America Healthy Again (MAHA) movement.
Calley Means, a former administration adviser and a prominent MAHA advocate, alleged earlier this month that Overton helped develop the policy easing regulatory standards for fruit-flavored vapes, according to reporting by STAT and The Washington Post.
The allegations revealed divisions among administration officials over how the FDA should balance youth prevention with access for adult smokers to potentially less harmful nicotine alternatives.
During her September 24 confirmation hearing, Overton emphasized the administration’s commitment to preventing youth access to vaping products while acknowledging that adult smokers use flavored alternatives to help them quit.
She also stated that the FDA must adhere to the statutory public health standard when assessing individual products.
The dispute follows two significant FDA decisions in May.
On May 5, the agency issued marketing authorizations for fruit-flavored Glas G2 vapor products. On May 8, it issued enforcement guidance outlining when certain unauthorized e-cigarettes and nicotine pouch products with pending applications would generally not be prioritized for enforcement.
The guidance does not constitute marketing authorization and is currently the subject of a federal legal challenge by Campaign for Tobacco-Free Kids and other plaintiffs.
As NI reported on November 17, a federal judge in Maryland granted American Vapor Manufacturers and Altria subsidiaries Helix Innovations and NJOY permission to join the defense of the FDA’s enforcement guidance.
Overton’s nomination, however, faced resistance that extended well beyond nicotine policy.
Republican senators questioned her involvement in the administration’s efforts to revise childhood vaccination recommendations, while abortion-related policy disputes added further complications.
Senate HELP Committee Chairman Bill Cassidy, a Louisiana Republican and physician, disputed suggestions that Overton lacked the necessary votes, saying he believed her nomination could have advanced through the committee and the full Senate.
According to the Associated Press, Cassidy attributed the remaining impasse to anti-abortion Republicans’ demands for additional commitments from the administration.
Democratic Sen. Ed Markey of Massachusetts also publicly announced his opposition. “The FDA needs a leader who will stand up for science and for our kids’ safety, not one who stood by while both were undermined,” Markey told Fierce Pharma before the nomination was withdrawn.
Reuters reported that Kansas Republican Sen. Roger Marshall, an obstetrician who lost his reelection bid earlier this month, is under consideration as a potential replacement.
The White House has not announced any additional nominee.
Kyle Diamantas, the FDA’s former deputy commissioner for food, continues to serve as acting commissioner, a role he has held since Makary’s departure in May.
The upcoming change in congressional leadership adds another complication. Democrats are set to regain control of the Senate in January after the November midterm elections, potentially making it more difficult to confirm Trump’s next FDA nominee.




